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In Brief
Bruning et al. report that blocking fatty acid synthase (FASN) in endothelial cells (ECs) reduces angiogenesis by impairing EC proliferation. Mechanistically, FASN inhibition elevates the malonyl-CoA substrate pool, thereby increasing posttranslational malonylation of mTOR and decreasing the pro-angiogenic mTORC1 activity. INTRODUCTION Fatty acid synthase (FASN) mediates de novo lipid synthesis by catalyzing the production of palmitate from acetylcoenzyme A (CoA), malonyl-CoA, and NADPH. Palmitate is used for the synthesis of more complex fatty acids (FAs), plasma membrane structures, and post-translational protein palmitoylation (Rohrig and Schulze, 2016) . In contrast to most non-transformed cells, which satisfy their demand from dietary lipids, cancer cells often synthesize up to 95% of FAs de novo despite sufficient dietary supply (Zaidi et al., 2013) . Not surprisingly, lipogenesis has been implicated in cancer cell biology (Rohrig and Schulze, 2016) .
Limited evidence has implicated FASN in angiogenesis. In vitro, the FASN blocker orlistat inhibits EC proliferation, associated with downregulation of vascular endothelial growth factor receptor 2 (Browne et al., 2006) , but it is unknown whether the latter is cause or consequence of FASN inhibition. Constitutive FASN loss in ECs and hematopoietic cells decreases angiogenesis in ischemia (Wei et al., 2011) . Nonetheless, the role of endothelial FASN loss in physiological development in vivo has not been studied, neither the therapeutic potential of FASN blockade in pathological ocular angiogenesis.
Malonyl-CoA participates in (patho-)physiological processes (Saggerson, 2008) . While FASN inhibition impaired palmitoylation due to reduced palmitate synthesis (Wei et al., 2011) , (A and B) Incorporation of carbons from [U-14C]-acetate in the fatty acid (FA) fraction of control (ctrl) and FASNKD ECs (n = 3) (A) or control and orlistat-treated (10 mM) ECs (n = 4) (B). DPM, disintegrations per minute. (C) Incorporation of carbons from [U-14C]-acetate in the FA fraction of ECs in the presence or absence of FAs in the medium (n = 3). DPM, disintegrations per minute. (D) Violin plots visualizing the log2 fold-change distribution in gene expression (gray area) in murine and human tumor ECs versus their counterpart normal healthy ECs. The red dot indicates where FASN is located in the distribution. Data are based on a meta-analysis of publicly available transcriptome datasets of murine B16 melanoma (B16 mel); murine medulloblastoma (MB-Shh, MB-Wnt); human hepatocellular carcinoma (HCC-CD105, HCC-CD31); human colorectal cancer (CRC, CRCLM) and human renal cancer (RCC). p = 1.0 3 10_20 (Fisher's method). (E) Incorporation of carbons from [U-14C]-glucose in the FA fraction of ECs (EC), breast cancer cell lines MDA-MB-231 (MDA-231), MDA-MB-468 (MDA-468), T47D, and MCF7, hepatocellular carcinoma cells HuH7 and HepG2, and prostate cancer cells DU145 in their optimal growth medium (n = 3). DPM, disintegrations per minute. (F and G) [3H]-Thymidine incorporation into DNA (proliferation assay) in control and FASNKD ECs (n = 4) (F), and in control or orlistat-treated ECs (n = 5) (G). DPM, disintegrations per minute. (H) Scratch wound migration assay using mitotically inactivated (mitoC) control or FASNKD ECs (n = 3). (I) Number of mitoC-treated control and FASNKD ECs that traversed the membrane in a Boyden chamber (expressed relative to control; n = 3). (J and K) Analysis of random cell-motility tracks obtained by time-lapse imaging of GFP+ ECs (transduced with a lentiviral vector expressing GFP), for speed (J) or directional persistence of EC movement (K) in control and FASNKD ECs (n = 4). consequences of elevated levels of malonyl-CoA as a result of FASN inhibition in ECs were not considered. Malonyl-CoA can be non-enzymatically used for protein lysine malonylation, a recently identified post-translational modification (PTM) that can alter protein activity (Peng et al., 2011) . Even though protein malonylation is evolutionarily conserved from bacteria to mammals, the functional consequences and stoichiometry of this PTM are poorly characterized (Du et al., 2015; Nishida et al., 2015) , and have never been determined in a single study. Here, we explored whether FASN might regulate angiogenesis via malonylation of key targets.
Figure 1. Role of Endothelial Fatty Acid Synthase in Vessel Sprouting

RESULTS
Fatty Acid Synthesis in Endothelial Cells
We explored whether human umbilical venous ECs (referred to hereafter as ECs) synthesized palmitate de novo. To mimic in vivo physiological conditions, we used physiological concentrations of palmitate (100-120 mM), acetate (200-500 mM), and glucose (5.5 mM) and added trace amounts of 14C-labeled acetate (<0.1% of the concentration of the cold acetate). When quantifying the incorporation of labeled carbons into the FA fraction, we detected measurable levels of FA synthesis in ECs, despite available palmitate in the medium (Figures 1A and 1B) .
To assess whether this signal was due to FASN activity, we silenced its expression in ECs using lentiviral vectors encoding two non-overlapping FASN-specific short hairpin RNAs (shRNAs) (shFASN) and non-overlapping RNAi oligomers, which lowered FASN levels (Figures S1A-S1F). FASN knockdown (FASNKD) or use of the FASN blocker orlistat reduced 14C label incorporation into FAs in ECs (Figures 1A and 1B) , similarly as in other cell types (Kridel et al., 2004) . Notably, orlistat inhibited FASN in ECs at concentrations 10-to 20-fold lower than those used to inhibit FASN in cancer cells . When using FA-depleted medium, ECs upregulated FASN protein ( Figure S1G ) and FA synthesis levels ( Figure 1C ). We reanalysed in-house transcriptomics data of murine tumor ECs (TECS) versus normal ECs (NECs) (Cantelmo et al., 2016) , as well as published transcriptomics studies of murine and human TECs versus NECs (Phoenix et al., 2016; Roudnicky et al., 2013; Wragg et al., 2016) . This meta-analysis revealed that FASN was overexpressed in TECs ( Figure 1D ; p = 1.0 3 10_20). Compared with cancer cells, known to express FASN (Hou et al., 2008; Hunt et al., 2007) , ECs had lower FASN protein levels ( Figure S1H ). Incorporation of 14C label from [U-14C]glucose into FAs was lower in ECs than in cancer cells, except for MCF7 cells ( Figure 1E ).
FASN Promotes Vessel Sprouting In Vitro
FASNKD or a low concentration of orlistat (10 mM) decreased EC proliferation ( Figures 1F, 1G , and S1I-S1L). As the outcome of EC migration assays is influenced by EC proliferation, we analyzed the migratory behavior of ECs upon mitotic inactivation by mitomycin C (mitoC) (De Bock et al., 2013) . FASNKD did not impair migration of mitoC-treated ECs, as measured in the scratch wound assay ( Figure 1H ) and only minimally reduced EC motility in the Boyden chamber assay ( Figure 1I ). Analysis of the velocity and directionality of spontaneous migration confirmed that FASNKD did not reduce EC motility ( Figures 1J and 1K ). Using the EC spheroid model (Schoors et al., 2015) , FASNKD or orlistat reduced EC sprouting ( Figures 1L-1P and S1M-S1P). MitoC impaired vessel sprouting, but FASNKD was unable to further reduce sprouting upon mitoC treatment, showing that FASNKD impaired vessel sprouting primarily by reducing EC proliferation, not migration ( Figures 1N-1P and S1M).
FASN Gene Deletion in ECs Impairs Physiological Angiogenesis In Vivo
To study the in vivo relevance of endothelial FASN deficiency, we crossed FASNlox/lox mice (Wei et al., 2011) with VEcadherin(PAC)-CreERT2 mice, a tamoxifen-inducible EC-specific Cre-driver line (Benedito et al., 2009 ). Treatment of doubletransgenic pups with tamoxifen at postnatal day 1 (P1) to P3 yielded viable FASNDvEC mice, in which FASN was deleted in ECs ( Figures S2A and S2B ). Staining of retinal vessels with isolectin-B4 (IB4) revealed that EC loss of FASN reduced the number of vascular branch points and total vascular area (Figures 2A-2E ). The vascular defects in FASNDvEC mice were due to reduced EC proliferation ( Figures 2F-2H ), and FASNDvEC mice had a normal number of filopodia per 100-mmvascular front perimeter ( Figures 2I-2K ). The vascular defect in FASNDvEC mice was not due to vessel regression, as staining for IB4 and collagen IV did not reveal a change in the fraction of empty sleeves ( Figures  2L-2N ). Vessel maturation was normal in FASNDvEC mice ( Figures S2C-S2E ). Similar effects were seen in conditional FASNDEC mice when a tamoxifen-inducible platelet-derived growth factor Cre-recombinase line was used as EC- 
Effects of FASN Silencing on EC Metabolism
FASNKD did not affect glycolysis, glucose, or glutamine oxidation ( Figures 3A-3C ), but reduced FA oxidation (FAO), though by no more than 30% ( Figure 3D ), consistent with the fact that malonyl-CoA inhibits carnitine palmitoyltransferase 1A (CPT1A, a rate-controlling enzyme of FAO) and malonyl-CoA levels were elevated in FASNKD cells (see below). FASNKD did not affect label incorporation from [U-13C]-glucose or [U-13C]-glutamine into tricarboxylic acid (TCA) cycle intermediates, but slightly reduced label incorporation from [U-13C]-palmitate, in line with the reduced FAO ( Figures S3A-S3C ). FASN silencing or blockade did not cause energy distress, as determined by measuring the energy charge or p-AMPK levels ( Figures 3E, 3F , and S3D). This is not surprising, since FAO contributes only minimally (<5%) to the total ATP production in ECs, which relies primarily on glycolysis (De Bock et al., 2013) , and FAO was reduced only moderately. Measurements of cellular reactive oxygen species (ROS) levels in baseline and upon challenge with exogenous H2O2 ( Figure 3G ), in combination with quantification of oxidized glutathione (GSSG) levels ( Figure 3H ), revealed that FASNKD did not cause redox imbalance or the ability of ECs to cope with exogenous oxidative stress. Even though FAO supports EC proliferation by providing acetyl-CoA to sustain the TCA cycle for dNTP synthesis in conjunction with an anaplerotic carbon source (Schoors et al., 2015) , the modest reduction of FAO in FASNKD cells did not likely explain their proliferation defect ( Figures S3E-S3N ).
FASN Silencing Moderately Affects Palmitate Levels in ECs
Impairment of proliferation and viability of cancer cells upon inhibition of FASN or acetyl-CoA carboxylase (ACC) has been attributed to depletion of cellular palmitate pools by 50%-97%, sufficient to cause ER stress and apoptosis (Ventura et al., 2015) . FASNKD lowered palmitate levels only by ±20% in ECs ( Figure 3I ), likely because ECs can take up FAs from the medium or recycle membrane lipids (Rohrig and Schulze, 2016) . Import of [U-14C]-palmitate was not compensatorily increased by FASNKD ( Figure S4A ) or orlistat, in contrast to sulfo-N-succinimidyl oleate (SSO), an inhibitor of FA translocase CD36 (Kuda et al., 2013) (Figure S4B ), suggesting that the palmitate uptake capacity of ECs is sufficient to maintain cellular palmitate pools. Consistent with reduced de novo palmitate synthesis, the fraction of monounsaturated fatty acyl chains was moderately decreased in FASNKD ECs ( Figures S4C and S4D ). The reduced pool of palmitate in FASNKD ECs was insufficient to cause ER stress and cell death (Figures S4E-S4I and S5A). Unlike cancer cells (Svensson et al., 2016) , supplementation of palmitate, elevating cellular palmitate pools in FASNKD ECs even slightly above the levels in control cells ( Figure S5B ), did not rescue the FASNKD sprouting defect ( Figure 3J ). Thus, the sprouting defect of FASNKD ECs was not due to the depletion of cellular palmitate pools.
FASN Silencing Increases Malonyl-CoA Levels
We then explored whether FASNKD enhanced the accumulation of its substrate malonyl-CoA. Lipogenesis involves conversion of acetyl-CoA to malonyl-CoA by ACC, and the use of malonyl-CoA and acetyl-CoA by FASN to synthesize palmitate. FASNKD or orlistat substantially elevated malonyl-CoA levels, without affecting acetyl-CoA levels (Figures 4A,  4B , and S5C). To explore whether the elevated malonyl-CoA levels contributed to the sprouting defects, we silenced the expression of acetyl-CoA carboxylase 1 (ACC1), which is expressed more abundantly than its isoenzyme ACC2 in ECs ( Figure S5D ). ACC1 knockdown (ACC1KD; lowering ACC1 mRNA levels by 83%) alone did not affect malonyl-CoA levels, but when both FASN and ACC1 were silenced, malonyl-CoA levels were no longer increased ( Figure 4C ). Silencing of malonyl-CoA decarboxylase (catalysing the reverse reaction of ACC1) and of SIRT5 (a de-malonylase [Nishida et al., 2015] ) did not induce changes in protein malonylation in ECs (not shown). ACC1KD alone reduced vessel sprouting and EC proliferation ( Figures 4D, 4F , 4H, and 4I) (a more prominent anti-mitogenic effect was reported for cancer cells [Svensson et al., 2016] ). More importantly, however, when both FASN and ACC1 were silenced together, EC proliferation and vessel sprouting were similar relative to ACC1KD cells, showing that the anti-proliferative effect of FASNKD was abrogated by ACC1KD ( Figures 4D-4I and S5E ). Thus, FASNKD impaired sprouting and EC proliferation partly by elevating malonyl-CoA levels. 
FASN Silencing Induces Malonylation of mTOR
We explored whether the increased malonyl-CoA levels influenced protein malonylation, a poorly studied non-enzymatic PTM driven by substrate levels (Peng et al., 2011) . Immunoblotting of lysates for malonylated lysine residues (Kmal) revealed that FASNKD or orlistat elevated general Kmal levels in ECs (Figures 5A and S5F ). To identify malonylated proteins, we performed a proteomics screen using an anti-Kmal antibody to enrich Kmal peptides and analyzed Kmal peptides as reported by Colak et al. (2015) . We identified nearly 100 Kmal sites in 64 different proteins, of which 62 were reported in other malonylome screens, validating our approach (Table S1 ). Among the proteins with Kmal sites, we identified targets involved in pathways previously shown to be modified by lysine malonylation, including glycolysis, pentose phosphate pathway, and cytoskeleton remodeling (Table S1 ) (Nishida et al., 2015) . (C) Representative western blots of immunoprecipitated (IP) endogenous malonylated proteins (Kmal; left blot) or mTOR (right blot) and immunoblotted for the reciprocal proteins in control and FASNKD ECs. Actin was used as loading control. Arrowheads indicate malonylated (Kmal) or total mTOR band. Densitometric analysis of the Kmal mTOR to total mTOR ratio, expressed relative to control, is shown beneath the blots (n = 3). (D) Stoichiometry of mTOR-K1218 malonylation determined by novel LC-MS/MS methods, in control and FASNKD ECs (n = 4). (E) Representative immunoblot of total (p70S6K) and phosphorylated (p-p70S6K threonine 389 [T389]) p70S6K in control (ctrl) and FASNKD ECs. Actin was used as loading control. The mTORC1 inhibitor rapamycin (Rap) (20 nM) and mTORC1/2 inhibitor Torin2 (100 nM) were used as positive controls. Densitometric quantification of the p-p70S6K/p70S6K ratio, expressed relative to ctrl, is shown beneath the blots (n = 3). (F) Representative immunoblot of total 4EBP1 and phosphorylated p-4EBP1 in control and FASNKD ECs. Actin was used as loading control (ctrl). The mTORC1 inhibitor rapamycin (Rap) (20 nM) and mTORC1/2 inhibitor Torin2 (100 nM) were used as positive controls. Densitometric analysis of the ratio between the high phosphorylated g over low phosphorylated a form of p-4EBP1, expressed relative to ctrl, is shown beneath the blots (n = 3). (G) [3H]-Tyrosine incorporation (protein synthesis) in control (ctrl) and FASNKD ECs, treated with control vehicle, or 20 nM rapamycin (Rap) or 100 nM Torin2 (n = 4). DPM, disintegrations per minute. Data are mean ± SEM. *p < 0.05 by ANOVA (G) or standard two-tailed t test with Welch's correction (C-F); ns, not significant. See also Figures S5 and S6 ; Tables S1 and S2.
Among the identified Kmal proteins, we focused on the mechanistic target of rapamycin (mTOR), a serine/threonine kinase activated by anabolic signals (Saxton and Sabatini, 2017) , as it controls lipid synthesis, cell growth, metabolism, and other cell processes in response to nutrition (Saxton and Sabatini, 2017) . A report that mTOR complex 1 (mTORC1) blockade by rapamycin inhibits ocular angiogenesis (Yagasaki et al., 2014b) primed our interest to focus on this target. The mTOR kinase nucleates two protein complexes named mTORC1 and mTORC2. The proteomic analysis identified only one malonylated lysine residue in mTOR (K1218), showing a characteristic tandem mass spectrometry (MS/MS) spectrum including C-terminal y-ions and amino-terminal b-ions (Table S1 and Figure 5B ).
Immunoprecipitation of endogenous mTOR followed by immunoblotting for Kmal (also in the reverse order for FASNKD cells) confirmed that mTOR was malonylated, and that malonylated mTOR levels were increased in FASNKD or orlistat-treated ECs (Figures 5C and S5G) . The weak immunoblot signals are attributable to the fact that only one lysine is malonylated in mTOR and, possibly, that only a fraction of the endogenous mTOR pool in ECs is malonylated. Indeed, when generating a tryptic peptide containing a stably malonylated K1218 of mTOR to measure the malonylation stoichiometry via MS, we found 4.5% of the mTOR pool to be malonylated in FASNKD ECs ( Figure 5D ).
Malonylation of mTOR Reduces mTORC1 Activity
To assess whether mTOR malonylation affected the activity of its complexes, we analyzed phosphorylation of the downstream targets of mTORC1 (eukaryotic translation initiation factor 4Ebinding protein 1 [4EBP1]; p70 S6 kinase [p70S6K]) and mTORC2 (Akt), using the mTORC1 inhibitor rapamycin and the mTORC1/mTORC2 inhibitor torin2 as positive controls (Saxton and Sabatini, 2017) . FASNKD (inducing mTOR malonylation) reduced mTORC1's activity to phosphorylate p70S6K and 4EBP1 ( Figures 5E and 5F ). In line with reports that 4EBP and p70S6K regulate protein synthesis downstream of mTORC1 (Saxton and Sabatini, 2017) , de novo protein synthesis was reduced upon FASNKD ( Figure 5G ). Treatment of control cells with rapamycin or torin2 reduced protein synthesis, which could not be further decreased by FASNKD ( Figure 5G ). In agreement with findings that p70S6K regulates cell size (Saxton and Sabatini, 2017) , FASNKD reduced EC size ( Figure S5H) .
In contrast, FASNKD lowered phosphorylation of mTORC2's target Akt ( Figure S6A ), but less prominently than of mTORC1 targets, and not consistently across different assays (see below). Possibly, the effect by FASNKD on p-Akt relates to the reduced confluence of these cells (cell-cell contacts activate Akt [Taddei et al., 2008] ). Though not extensively documented, certain PTMs of mTOR correlate with changes in the activity of mTORC1, not of mTORC2 (Rosner et al., 2010) . While remaining unexplained, the more selective regulation of mTORC1, rather than mTORC2, pathway activity by mTOR malonylation may thus not be surprising. Additional ACC1KD in FASNKD ECs normalized the malonylated mTOR levels to those in control cells and restored mTORC1's activity ( Figures S6B-S6D) ; FASN overexpression yielded similar results ( Figures S6E and S6F) .
Malonylation of mTOR upon FASNKD reduced the enzymatic activity of mTORC1, in two complementary assays (radioactive phosphor donor [Dunlop et al., 2009] ; commercial ELISA-based kit) ( Figures 6A and 6B) , without, however, affecting its stability or intracellular localization (Figures S6G, S6H , and S7A). FASN inhibition by orlistat yielded largely similar results ( Figure 6B ), although phosphorylation of Akt was unchanged (see below). We also assessed whether mTOR malonylation decreased mTORC1's activity independently of FASN inhibition by employing malonyl-NAC (Nacetylcysteamine), a cell-permeable agent capable of directly inducing cellular protein malonylation (Kulkarni et al., 2017) . Similar to FASNKD cells, malonyl-NAC treatment of control ECs reduced mTORC1's activity ( Figure 6B ) and target phosphorylation ( Figure 6C ), illustrating that direct malonylation of mTOR, independently of FASN manipulation, sufficed to reduce mTORC1's activity.
mTOR Mutagenesis Studies
To test whether the increased mTOR malonylation contributed to the vascular defects upon FASN inhibition, we mutated K1218 of mTOR into glutamic acid (E) in order to mimic constitutive malonylation (mTORK/E) (Nishida et al., 2015) . To avoid any confounding interpretation resulting from endogenous wild-type (WT) mTOR expression, we silenced mTOR (lowering mRNA levels by 60%-70%; Figure S7B ) and expressed wild-type mTOR (mTORWT) or mTORK/E, both resistant to the mTOR-specific shRNA ( Figure S7B ). To avoid additional stress for ECs resulting from multiple viral transductions, we used orlistat to inhibit FASN. Compared with mTORWT, mTORK/E expression reduced protein synthesis in control cells to similar levels as in orlistat-treated mTORWT cells, while protein synthesis was not further reduced by orlistat in mTORK/E cells ( Figure 6D ). Similar results were obtained when analyzing phosphorylation of p70S6K and 4EBP1 ( Figure 6E ) and vessel sprouting ( Figures 6F-6M and S7C) . Also, mTORK/E reduced mTORC1's enzymatic activity to levels similar to those of FASNKD or orlistat ( Figure 6B ). https://doi.org/10.1016/j.cmet.2018.07.019 HEK293T cells overexpressing either myc-tagged wild-type mTOR (mTORWT) (first 4 columns) or a myc-tagged highly active E2419K mutant of mTOR (last 4 columns), with or without addition in the kinase reaction mixture of recombinant Rheb Q64L, a highly active mutant of the mTORC1 activator Rheb. Middle (rows 2 and 3): immunoblotting for myc-mTOR (row 2) or HA-RAPTOR (row 3) of lysates of the above listed cells after immunoprecipitation of the mTORC1 complex using anti-myc antibodies. Immunoblotting for myc-mTOR is shown to confirm mTOR overexpression; immunoblotting for HAraptor is shown as loading control for the kinase assay. Bottom: representative autoradiograms of [32P]-4EBP1. Densitometric quantification of the [32P]-4EBP1 bands, expressed as fold change relative to control (column 1) is shown beneath the autoradiogram. The more active E2419K mutant of mTOR was overexpressed to enhance the AR signal (last 4 lanes).
(B) mTORC1 enzymatic activity (K-LISA mTOR activity kit [Millipore]) in control (ctrl), FASN-silenced (FASNKD), orlistat-treated ECs, ECs expressing mTOR harboring a K1218E mutation (mTORK/E, malonylation mimicking), and ECs treated with malonyl-NAC (mNAC, a cellpermeable malonyl-CoA mimic) (n = 3). Values were normalized to protein input and are expressed as fold change relative to control. (C) Representative immunoblot of Kmal, total and phosphorylated p70S6K, and actin as loading control, in control (ctrl) and FASN-silenced (FASNKD) ECs, ECs expressing mTOR harboring a K1218E mutation (mTORK/E, malonylation mimicking), and ECs treated with malonyl-NAC (mNAC, a cell-permeable malonyl-CoA mimic). Densitometric quantification of the p-p70S6K/p70S6K ratio, expressed relative to control, is shown beneath the blot (n = 3). (D) [3H]-Tyrosine incorporation in control and orlistat (10 mM)-treated ECs, silenced for endogenous mTOR (mTORKD) as indicated and expressing a wild-type mTOR (mTORWT) or mTOR harboring a K1218E (mTORK/E) mutation (both resistant to the mTOR shRNA) (n = 4). DPM, disintegrations per minute. (E) Representative immunoblot of total and phosphorylated levels of the mTORC1 targets p70S6K and 4EBP1 in control ECs and ECs silenced for endogenous mTOR (mTORKD) with or without overexpression of wild-type mTOR (mTORWT) or mTOR harboring a K1218E (mTORK/E) mutation (both resistant to the mTOR shRNA) and with or without FASN inhibition (orlistat). Densitometric quantification of the p-p70S6K/p70S6K ratio or of the ratio between the high phosphorylated g over low phosphorylated a form of 4EBP1 (expressed relative to ctrl ECs) is shown beneath the blots (n = 3). (F) Quantification of vessel sprouting from spheroids shown in (G) to (M) (n = 3). (G-M) Representative phase-contrast images of control (ctrl) and orlistat-treated EC spheroids using wild-type ECs (G and H), or ECs silenced for endogenous mTOR (mTORKD) and expressing mTOR WT (mTORWT) (I and J) or mTOR K1218 mutant (mTORK/E) (both resistant to the mTOR shRNA) (K and L). (M) shows a representative spheroid using mTORKD ECs. Scale bars, 200 mm. Data are mean ± SEM. In (A), *p < 0.05, #p < 0.05 for FASNKD versus its corresponding FASN wild-type in each condition. In (B), (D), and (F), *p < 0.05 by ANOVA. In (E), *p < 0.05 for orlistat versus its corresponding control, or for mTORKD versus control (column 1), by standard two-tailed t test with Welch's correction. In (C), *p < 0.05 versus its respective control and #p < 0.05 for mNAC versus FASNKD, determined by ANOVA followed by t test. ns, not significant. See also Figure S7 .
To confirm specificity, we mutated mTOR K1218 into arginine (mTORK/R) in order to prevent malonylation, an approach widely used in the acetylation field (Baeza et al., 2016) , though never performed in the malonylation field to date (in higher eukaryotes). Overexpression of mTORWT in control cells (in which endogenous mTOR expression was not silenced) elevated mTOR malonylation upon FASNKD ( Figure S7D ). In contrast, overexpression of mTORK/R in control cells elevated mTOR malonylation much less upon FASNKD ( Figure S7D ), the residual increase resulting from endogenous WT mTOR. Using a similar strategy as employed for mTORK/E, we observed that mTORK/R abrogated the decrease of p-p70S6K/p70S6K levels upon FASNKD ( Figure S7E ). When analyzing vessel sprouting, overexpression of mTORK/R in control cells induced a small baseline effect (consistent with reports of mTORK/R in other assays [Gorsky et al., 2016] ), but abrogated the decrease upon FASNKD as observed in mTORWT-expressing cells ( Figure S7F ). As mentioned, orlistat did not reduce p-Akt/Akt levels in control ECs or ECs re expressing mTORWT, mTORK/E, or mTORK/R ( Figure S7G ).
Pharmacological FASN Blockade Reduces Angiogenesis and Vascular Defects
Pharmacological compounds blocking FASN (orlistat) are being used to treat obesity (Point et al., 2016) . However, in preclinical models, orlistat induces weight loss when used at a very high dose (240 mg/kg/day) (Kridel et al., 2004) . We therefore used orlistat at a low dose (10 mg/kg/day) that did not cause body weight loss ( Figure 7A ). Treatment of pups with orlistat from P1 to P4 caused qualitatively similar vascular changes as observed in FASNDEC mice, including reduced vessel branching and EC proliferation, without affecting EC migration ( Figures 7B-7G) . To test the therapeutic potential of FASN blockade in pathological angiogenesis, we used the model of retinopathy of prematurity (ROP), since the vascular tufts induced by ischemia primarily consist of proliferating ECs (Schoors et al., 2015) . Treatment of pups with a low dose of orlistat during the vascular proliferation phase reduced vascular tuft formation ( Figures 7H-7J ). Immunostaining revealed reduced phosphorylated S6 immunoreactive levels in vascular tufts in orlistat-treated mice similar to rapamycin-treated mice ( Figures 7K-7O ). Additional staining experiments confirmed reduced levels of phosphorylated p70S6K and unchanged levels of phosphorylated Akt in ECs freshly isolated from FASNvDEC mice, and in pulmonary ECs on fixed lung from FASNvDEC mice ( Figures S7H-S7L ). Thus, FASN blockade with a low dose of orlistat can inhibit pathological ocular neovascularization by reducing mTOR activity.
DISCUSSION
In addition to mediating de novo lipid synthesis, FASN in ECs indirectly controls PTM of target proteins via lysine malonylation, in particular mTOR, a prime regulator of metabolism. mTOR malonylation upon FASN inhibition reduced mTORC1's enzymatic activity, contributing to vascular defects. Identification of mTOR K1218 Malonylation Using an unbiased proteomic approach in FASNKD ECs, along with complementary biochemical validation, we established that mTOR is malonylated at K1218, embedded in the ICRIVKGYTLA amino acid sequence, containing amino acids (K, R, G, A, V, Y, I) that are often enriched in a lysine malonylation consensus site (Nishida et al., 2015) . K1218 in mTOR is acetylated in cancer cells (Choudhary et al., 2009) . Since acetylation and malonylation modify lysine residues (Nishida et al., 2015) , this finding raises the question of whether mTOR K1218 may be a key node for mTORC1 activity regulation by metabolite second messengers such as malonyl-CoA and acetyl-CoA (Pietrocola et al., 2015) . Notably, K1218 in mTOR is conserved in Homo sapiens, Mus musculus, and multiple other species (Table S2) . Nonetheless, we acknowledge that increased malonylation of other targets upon FASN inhibition may contribute to the impaired neovascularization. Stoichiometry of mTOR K1218 Malonylation Quantification of the absolute levels of stoichiometry of protein malonylation has never been successfully achieved, due to spontaneous decarboxylation of the malonyl moiety on standard peptides. To date, only one study reported an indirect estimate of malonylation stoichiometry using SILAC ratios (Colak et al., 2015) . We developed a targeted liquid chromatography-MS assay for quantification of absolute levels of malonylated versus total mTOR, employing a malonylated stable isotope labelled reference peptide (synthesized with Fmoc-Lys(mono-tert-butylmalonate)-OH as stable precursor for incorporation of the malonylated Data are mean ± SEM. *p < 0.05 by standard two-tailed t test with Welch's correction; ns, not significant. lysine) and five additional non-modified mTOR peptides as internal standards. Using this assay (useful for future malonylation stoichiometry studies), we reliably quantified the absolute malonylation stoichiometry. This analysis showed mTOR malonylation levels of 4.5% upon FASNKD.
These stoichiometry levels may appear low at first sight, but they are nonetheless consistent with reports for other PTMs, in particular acetylation. Indeed, most acetylation sites have very low stoichiometry, not higher than 0.5% (Weinert et al., 2015) . An acetylation stoichiometry of 1% is already considered ''high,'' with only five out of thousands of sites having a stoichiometry >5%, and only two sites with a stoichiometry of >10% (Weinert et al., 2015) . Studies in other organisms confirmed these data (Meyer et al., 2016) . Malonylation cannot be compared with phosphorylation as PTM, as the latter can occur at a much higher stoichiometry, especially during the cell cycle (80%-90% [Olsen et al., 2010] ), although the stoichiometry of phosphorylation in response to other stimuli is at most 25% (Sharma et al., 2014) . Though not fully appreciated, subpools of a single protein can participate in different biological processes. To induce a biologically relevant effect, PTMs thus may only need to affect the active fraction, not the total protein pool (Baeza et al., 2016) . This active fraction might be much smaller than the total pool. Future work will be required to resolve these outstanding questions.
Functional Validation of mTOR K1218 Malonylation, Independent of FASN Inhibition
Protein lysine malonylation was only recently discovered (2011); by transferring a bulky, negatively charged acyl group to a lysine residue, malonylation has been proposed to alter the structure and function of the target protein (Nishida et al., 2015) . Indeed, we observed a reduction in mTORC1 pathway activation and, in particular, of mTORC1's enzymatic activity, as determined by two independent cell-free assays.
Site-specific mutagenesis of K1218 showed that malonylation of this residue regulates mTORC1 pathway activation and mTORC1's enzymatic activity, as well as vascular responses. In addition, use of malonyl-NAC revealed that direct malonylation of mTOR, independently of FASN inhibition, was sufficient to induce similar results. All this is consistent with a model whereby inhibition of mTORC1's activity upon FASN silencing or blockade is not an indirect epiphenomenon of FASN inhibition, but a direct effect of mTOR malonylation. The findings also suggest that a partial stoichiometry of mTOR malonylation may suffice and a high stoichiometry of mTOR malonylation is not required to https://doi.org/10.1016/j.cmet.2018.07.019 induce a biological effect (reduced mTORC1 activity). Regardless, to the best of our knowledge, no previous report in the malonylation field determined both the stoichiometry and the functional importance of a malonylation site through mutagenesis and functional validation.
Possible Translational Implications
Treatment with orlistat, the most widely used drug for obesity treatment (Point et al., 2016) , reduced ocular neovascularization. The more prominent angiogenesis inhibition in pathological than physiological settings may relate to the fact that ECs more actively proliferate in disease. Increased mTOR and S6 activity levels have been documented in retinal ECs in the ROP model, while mTORC1 blockade reduces ocular angiogenesis (Yagasaki et al., 2014a) . In agreement with our model, we observed a decrease of phosphorylated S6 levels in orlistat-treated ROP lesions. A more specific FASN blocker confirmed the orlistat results in the experiments tested (not shown). Confirming our earlier reports (De Bock et al., 2013; Huang et al., 2017; Schoors et al., 2015) , emerging evidence shows that EC metabolism differs from that of cancer and immune cells. First, orlistat induces anti-angiogenic effects at >10-fold lower doses than needed to impair tumor growth, offering opportunities to reconsider the use of specific FASN inhibitors as antiangiogenic agent in cancer patients. Second, in cancer cells, orlistat caused cell death by inhibiting mTORC1 , although in most studies the underlying molecular mechanism was not revealed. Our data identified a mechanism of FASN-dependent regulation of mTOR signaling. Third, ECs differ from cancer cells, in which FASN inhibition depletes the cellular palmitate content (Ventura et al., 2015) . These EC-specific properties warrant consideration of FASN as an attractive target to inhibit pathological angiogenesis.
Limitations of the Study
While our study highlights that a low mTOR malonylation stoichiometry suffices to affect mTORC1's enzymatic activity, the precise molecular details of this phenomenon remain to be unveiled. Our data do not exclude that increased malonylation of other proteins upon FASN inhibition may be involved in the impaired angiogenic response. Nevertheless, the data obtained using ECs expressing mTORK/E and mTORK/R mutants, in which malonylation of other proteins was not affected, support a role of mTOR signaling in the angiogenesis phenotype. Furthermore, it would also be insightful to evaluate more specific inhibitors of FASN, once available, for preclinical testing. In conclusion, we discovered a role and therapeutic potential of targeting FASN for pathological neovascularization.
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